Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 3Skin Neoplasms 1Neoplasms 1

Interventions

Cyclophosphamide 12aldesleukin 9fludarabine 8fludarabine phosphate 7pembrolizumab 6Ipilimumab 5Interleukin-2 5Nivolumab 4dabrafenib 2Vemurafenib 2Biopsy 2Aminolevulinic Acid 2varlilumab 1trametinib 1tilsotolimod 1spartalizumab 1sotigalimab 1sonidegib 1smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic 1glembatumumab vedotin 1eprenetapopt 1epacadostat 1encorafenib 1cemiplimab 1cabozantinib 1binimetinib 1bempegaldesleukin 1abobotulinumtoxinA 1X-Rays 1Tranexamic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Skin Neoplasms × sotigalimab × Clear all
NCT04337931 2024-02-13

A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma

Apexigen America, Inc.

Phase 2 Terminated
45 enrolled 14 charts
Dermatologic

Melanoma, Neoplasms, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡